Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following are excluded:
• •AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
• •Significant hepatic disease.
• •Thrombocytopenia.
• •Hypersensitivity to thymopentin.
• •Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
• •Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
• •Patients with the following are excluded:
• •AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
• •Significant hepatic disease.
• •Thrombocytopenia.
• •Hypersensitivity to thymopentin.
• •Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
• •Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
• •Prior Medication:
• •Excluded within 30 days of study entry:
• •Immunomodulatory or experimental therapy.
• •Excluded within 90 days of study entry:
• •Zidovudine (AZT).
• •Intravenous drug abuse.